Javascript must be enabled to continue!
Prevalence and Determinants of Subclinical Atherosclerosis in People Living with HIV on Antiretroviral Treatment in Hospitals in Kinshasa
View through CrossRef
Introduction: The objective of this work was to identify the traditional, emerging, and therapeutic cardiometabolic risk factors for subclinical atherosclerosis in human immunodeficiency virus (HIV)-infected patients under antiretroviral treatment in the era of dolutegravir (DGT) in hospitals in the Kinshasa, Democratic Republic of the Congo (DRC). Methods: This was a descriptive and analytical cross-sectional study held between January 2017 and December 2021 among people living with HIV (PLWHIV) on antiretroviral treatment (ART) for at least 6-months, supported in the structures of the Network Catholic of the Diocesan Office of Medical Works (BDOM) and at the University Clinics of Kinshasa (UCK). Subclinical atherosclerosis was defined by: pulse pressure (PP)≥60 mm Hg; a carotid intima-media thickness (CIMT)>0.8 mm and a systolic pressure index (SPI)<0.9. Logistic regression was used in the statistical study of associations. Results: A total of 321 PLWHIV on ART were recruited. The average age of PLWHIV was 51±11-years with a female predominance of 72% (n=231); the independent determinants of subclinical atherosclerosis were married (aOR: 4, 95% CI 1.5- 10.5; p<0.006), low socio-economic status (aOR: 10.7, 95% CI 2.3-48, 7 p<0.002), duration of HIV infection (ORa: 6.6, 95% CI 2.8-16; p<0.0001), duration of antiretroviral treatment ≥9-years (ORa: 0, 3, 95% CI 0.2-0.7; p<0.005) and the total cholesterol/ high-density lipoprotein-cholesterol ratio (CT/HDL-C) (ORa: 2, 95% CI 1.1-3.6; p=0.034). Dyslipidaemia (hyper low-density lipoprotein-cholesterol (LDL-C), hyper HDL-c and hypertriglyceridemia) has been identified in PLWHIV on DTG. The prevalence of subclinical atherosclerosis in PLWHIV on ART was 31.1% (n=116/321). Conclusion: Married people, low socioeconomic level, duration of HIV infection, duration of antiretroviral treatment beyond 9-years, and the CT/HDL-C ratio are identified as independent determinants of subclinical atherosclerosis in PLWHIV on ART in Kinshasa hospitals. Dyslipidemia is found in PLWHIV on DTG and the prevalence of subclinical atherosclerosis among PLWHIV on ART is low compared to that of Côte d’Ivoire.
Openventio Publishers
Title: Prevalence and Determinants of Subclinical Atherosclerosis in People Living with HIV on Antiretroviral Treatment in Hospitals in Kinshasa
Description:
Introduction: The objective of this work was to identify the traditional, emerging, and therapeutic cardiometabolic risk factors for subclinical atherosclerosis in human immunodeficiency virus (HIV)-infected patients under antiretroviral treatment in the era of dolutegravir (DGT) in hospitals in the Kinshasa, Democratic Republic of the Congo (DRC).
Methods: This was a descriptive and analytical cross-sectional study held between January 2017 and December 2021 among people living with HIV (PLWHIV) on antiretroviral treatment (ART) for at least 6-months, supported in the structures of the Network Catholic of the Diocesan Office of Medical Works (BDOM) and at the University Clinics of Kinshasa (UCK).
Subclinical atherosclerosis was defined by: pulse pressure (PP)≥60 mm Hg; a carotid intima-media thickness (CIMT)>0.
8 mm and a systolic pressure index (SPI)<0.
9.
Logistic regression was used in the statistical study of associations.
Results: A total of 321 PLWHIV on ART were recruited.
The average age of PLWHIV was 51±11-years with a female predominance of 72% (n=231); the independent determinants of subclinical atherosclerosis were married (aOR: 4, 95% CI 1.
5- 10.
5; p<0.
006), low socio-economic status (aOR: 10.
7, 95% CI 2.
3-48, 7 p<0.
002), duration of HIV infection (ORa: 6.
6, 95% CI 2.
8-16; p<0.
0001), duration of antiretroviral treatment ≥9-years (ORa: 0, 3, 95% CI 0.
2-0.
7; p<0.
005) and the total cholesterol/ high-density lipoprotein-cholesterol ratio (CT/HDL-C) (ORa: 2, 95% CI 1.
1-3.
6; p=0.
034).
Dyslipidaemia (hyper low-density lipoprotein-cholesterol (LDL-C), hyper HDL-c and hypertriglyceridemia) has been identified in PLWHIV on DTG.
The prevalence of subclinical atherosclerosis in PLWHIV on ART was 31.
1% (n=116/321).
Conclusion: Married people, low socioeconomic level, duration of HIV infection, duration of antiretroviral treatment beyond 9-years, and the CT/HDL-C ratio are identified as independent determinants of subclinical atherosclerosis in PLWHIV on ART in Kinshasa hospitals.
Dyslipidemia is found in PLWHIV on DTG and the prevalence of subclinical atherosclerosis among PLWHIV on ART is low compared to that of Côte d’Ivoire.
Related Results
HIV WGS - 400bp Amplicon Tiling - Oxford Nanopore Technology Protocol v1
HIV WGS - 400bp Amplicon Tiling - Oxford Nanopore Technology Protocol v1
OSPHL in collaboration with APHL, will evaluate the performance of the Oxford Nanopore Technology sequencers for HIV genome sequencing using a modified protocol of the ARTIC amplic...
The Hidden Problem of Cross-Reactivity: Challenges in HIV Testing During the COVID-19 Era: A Systematic Review
The Hidden Problem of Cross-Reactivity: Challenges in HIV Testing During the COVID-19 Era: A Systematic Review
Abstract
Introduction
Human immunodeficiency virus (HIV) and Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV2) surface glycoproteins, including shared epitope motifs, sho...
Capítulo 6 – HIV-AIDS, como tratar, o que fazer e o que não fazer durante o tratamento?
Capítulo 6 – HIV-AIDS, como tratar, o que fazer e o que não fazer durante o tratamento?
A infecção pelo vírus do HIV pode ocorrer de diversas maneiras, tendo sua principal forma a via sexual por meio do sexo desprotegido. O vírus do HIV fica em um período de incubação...
Prevalence and risk factors for subclinical atherosclerosis amongst adults living with HIV in University of Abuja Teaching Hospital, Gwagwalada
Prevalence and risk factors for subclinical atherosclerosis amongst adults living with HIV in University of Abuja Teaching Hospital, Gwagwalada
BackgroundSubclinical atherosclerosis characterizes cardiovascular diseases (CVD), and Human Immunodeficiency Virus (HIV) infection and antiretroviral therapy (ART) are identified ...
Field validation and application of the luminex triplex HIV assay to estimate HIV prevalence and HIV-1 incidence in Nigeria
Field validation and application of the luminex triplex HIV assay to estimate HIV prevalence and HIV-1 incidence in Nigeria
HIV cross-sectional surveys require multi-layered testing with several tests to estimate HIV prevalence and HIV-1 incidence. We evaluated the performance and accuracy of the newly ...
HIV profile of Neonatal Centre of Excellence Unit Admissions at the University Teaching Hospital-Children Division, Lusaka, Zambia after 2 decades of PMTCT: Retrospective pilot study
HIV profile of Neonatal Centre of Excellence Unit Admissions at the University Teaching Hospital-Children Division, Lusaka, Zambia after 2 decades of PMTCT: Retrospective pilot study
Abstract
Objectives
The aim of this study was to examine the prevalence of congenital HIV infection at the Neonatal Centre of E...
Evaluasi Terapi Antiretroviral Pasien HIV/AIDS
Evaluasi Terapi Antiretroviral Pasien HIV/AIDS
Pengobatan antiretroviral (ARV) bertujuan untuk menurunkan jumlah virus (viral load) serta menghambat perburukan infeksi oportunistik. Ketidakrasionalan terapi ARV akan menyebabkan...
Prevalence and associated factors of subclinical atherosclerosis in rheumatoid arthritis at the university hospital of Kinshasa
Prevalence and associated factors of subclinical atherosclerosis in rheumatoid arthritis at the university hospital of Kinshasa
Abstract
Background
Rheumatoid arthritis (RA) is associated with a 5 to 10 years reduction in life expectancy due to premature athero...

